Abstract

BackgroundElevated baseline neutrophil lymphocyte ratios (NLR) are now well established as a poor predictor of survival in renal cell carcinoma (RCC) and other cancers. Platelet Lymphocyte Ratios (PLR) have also...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The accuracy of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as a marker for gastrointestinal malignancies.
Ian Nora ... Ravi Shridhar
Journal of gastrointestinal oncology | VOL. 9
Ian Nora, et. al.Ian Nora ... Ravi Shridhar
01 Oct 2018
Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer.
Zhen-Yu Zou ... Ning Ning
Oncology letters | VOL. 11
Zhen-Yu Zou, et. al.Zhen-Yu Zou ... Ning Ning
09 Feb 2016
Accuracy of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting node positivity and metastatic disease in patients with gastrointestinal malignancies.
Matthew Doepker ... Justin Lee
Journal of Clinical Oncology | VOL. 34
Matthew Doepker, et. al.Matthew Doepker ... Justin Lee
01 Feb 2016
Abstract P3-08-67: Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio breast cancer patients according to HER2 overexpression
Joanna Huszno ... Jolanta Mrochem Kwarciak
American Journal of Cancer | VOL. 80
Joanna Huszno, et. al.Joanna Huszno ... Jolanta Mrochem Kwarciak
14 Feb 2020
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
EphA3 CAR T cells are effective against glioblastoma in preclinical models
Paulo Martins ... Rajiv Khanna
Journal for Immunotherapy of Cancer | VOL. 12
Paulo Martins, et. al.Paulo Martins ... Rajiv Khanna
07 Aug 2024
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses
Leesa Lertsumitkul ... Misty R Jenkins
Journal for Immunotherapy of Cancer | VOL. 12
Leesa Lertsumitkul, et. al.Leesa Lertsumitkul ... Misty R Jenkins
07 Aug 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker ... Massimo Di Nicola
Journal for Immunotherapy of Cancer | VOL. 12
Michael Schenker, et. al.Michael Schenker ... Massimo Di Nicola
06 Aug 2024
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
Zixiang Wang ... Baoxia Cui
Journal for Immunotherapy of Cancer | VOL. 12
Zixiang Wang, et. al.Zixiang Wang ... Baoxia Cui
06 Aug 2024
View more papers